About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Less Hospital Access to Outside Vendors and More Visits From State Pharmacy Boards
To avoid more fatalities and cases of fungal meningitis, as occurred from contaminated steroid products made at the New England Compounding Center, hospitals and their pharmacy directors must stay abreast of future changes in state and federal laws regarding compounding.
The authors review the challenges in diagnosis; the roles of stress, neurotransmitters, and biological factors; cognitive–behavior therapy; and pharmacological and nonpharmacological strategies in patients with anxiety.
Alexander Bystritsky, MD, PhD; Sahib S. Khalsa, MD, PhD; Michael E. Cameron, PhD; and Jason Schiffman, MD, MA, MBA
Novel Oral Anticoagulants for Venous Thromboembolism Prophylaxis After Total Hip or Knee Replacement
An Update on Rivaroxaban (Xarelto)
Novel anticoagulants represent promising alternatives to the traditional anticoagulants for VTE prophylaxis following hip and knee replacement surgery. Preliminary analyses for rivaroxaban suggest that it may be cost-effective and cost-saving in these patients.
Zachary Stacy, PharmD, BCPS
American Heart Association Scientific Sessions 2012
American Association for the Study of Liver Disease
American College of Rheumatology/Association of Rheumatology Health Professionals
Topics include serelaxin, aspirin alone, and aspirin combinations for cardiovascular disease; sovaprevir and pegylated interferon/ribavirin combinations for hepatitis C; apremilast and ustekinumab for psoriatic arthritis; and a newly approved drug, tofacitinib, for rheumatoid arthritis.
Using a parenteral syringe to prepare or give oral or enteral liquids can be deadly.
Matthew Grissinger, RPh, FASCP
Pharmacies can no longer bill Medicare directly for compounded drugs that they supply to physicians.
FDA approvals, drug indications, and updates
Tofacitinib (Xeljanz) for rheumatoid arthritis, perampanel (Fycompa) for partial-onset seizures, and teriflunomide (Aubagio) for relapsing multiple sclerosis
Marvin M. Goldenberg, PhD, RPh, MS
Abiraterone (Zytiga) for castration-resistant prostate cancer
Tamara Goldberg, PharmD, BCPS; and Evangelina Berrios-Colon, PharmD, MPH, BCPS, CACP